Cited by 322Antifungal resistance and susceptibilityHIV/AIDS oral health manifestationsOcular Infections and Treatments

Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance

Open access
Sangeorzan, Jon A., Bradley, Suzanne F., He, Xiaogang, Zarins, Lidija T., Ridenour, George L., Tiballi, Robert N., Kauffman, Carol A.·1994·The American Journal of Medicine

Abstract

Purpose To study the epidemiology of oral candidiasis and the effect of treatment of thrush in human immunodeficiency virus (HIV)-infected patients.Patients and methods We conducted a prospective observational study of 92 patients over 1 year, including a nonblinded, randomized treatment trial of thrush with clotrimazole troches or oral fluconazole. Oral sites were cultured monthly and when thrush occurred. Candida albicans strains were typed by contour-clamped homogeneous electric field (CHEF) electrophoresis. Changes in strains were evaluated over time and in regard to their associations with particular sites, episodes of thrush, relapse after treatment, and colonization of sexual partners. Susceptibility to fluconazole was tested and CHEF analysis was done on these strains to determine the epidemiology of fluconazole resistance.Results Yeasts colonized 84% of patients. C albicans accounted for 81% of all isolates and was separated into 34 distinct strains. Most patients had persistent carriage of 1 or 2 dominant strains of C albicans. Three couples shared strains. Nineteen different C albicans strains caused 82 episodes of thrush in 45 patients. CD4 < 200/microL was associated with development of thrush. Clinical cure rates were similar with fluconazole (96%) and clotrimazole (91%), but mycologic cure was better with fluconazole (49%) than clotrimazole (27%). Following mycologic cure, colonization recurred with the same strain 74% of the time. Colonization with Torulopsis glabrata and Saccharomyces cerevisiae increased after treatment with either drug, but these organisms were never a sole cause of thrush. In a subset of 35 patients followed for over 3 months in whom fluconazole susceptibilities were performed, minimum inhibitory concentrations (MICs) to fluconazole increased only in those on fluconazole prophylaxis. Clinical failure of fluconazole was associated with an MIC > or = 64 micrograms/mL in 3 patients, and with an MIC of 8 micrograms/mL in 1 patient. In 2 of these 4 patients, the prior colonizing strain developed fluconazole resistance. In the other 2, new resistant strains were acquired.Conclusions Many different strains of C albicans colonize and cause thrush in patients infected with HIV. Patients are usually persistently colonized with a single strain, and recurrences following treatment are usually due to the same strain. Transmission of strains may occur between couples. Fluconazole and clotrimazole are equally effective in treating thrush, but mycologic cure occurs more often with fluconazole. Fluconazole resistance in C albicans occurs most often in patients who have low CD4 counts and are taking fluconazole prophylactically for recurrent thrush. Fluconazole resistance may occur through acquisition of a new resistant strain or by development of resistance in a previously susceptible strain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/0002-9343(94)90300-x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In North American oral candidiasis (HIV/AIDS-positive) patients, the prevalence of fluconazole-resistant C. albicans isolates was found to be between 12% and 22%.

    “This has occurred with greatest frequency in the setting of patients suffering from HIV/AIDS during treatment for oropharyngeal candidiasis, where the prevalence of fluconazole-resistant C. albicans isolates in North American oral candidiasis (HIV/AIDS-positive) patients was found to be between 12% and 22%.38–42”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 43 · Cited by 322

Research works printed but not linked: 3

  1. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the inital manifestatron of the acquired immunodeficrency syndrome. NEJM. 1984;311:354-358.
  2. Bruatto M, Vidotto V, Marinuzzi G, et al. Candrda albicans biotypes in human rmmunodeficiency vrrus type l-infected patients with oral candidiasis before and after antifungal therapy. J Clrn Microbial. 1991;29:726-730.
  3. Vazquez JA, Sanchez V, Dmuchowski C, et al. Nosocomial acquisition of Candrda albicans: an epidemrologrc study. J Infect Dis. 1993;168:195-201.

Authors
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A.
Affiliations
University of Michigan (US)
Corresponding author
Kauffman, Carol A.
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1994-10
Volume
97
Issue
4
Pages
339-346
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2114055030
Cited by
322
References
43
Citations by year
2026: 1 · 2025: 4 · 2023: 5 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 12 · 2018: 6 · 2017: 17 · 2016: 6 · 2015: 9 · 2014: 8 · 2013: 4 · 2012: 13
FWCI
20.25
Type
journal article
Language
en
Open access
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV/AIDS oral health manifestations
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
oral candidiasis, HIV infection, Candida albicans, fluconazole resistance, antifungal prophylaxis, clotrimazole, candidiasis recurrence, persistent colonization, Candida glabrata, Saccharomyces cerevisiae, CD4 count, strain typing
MeSH terms
Adult, Candida, Candidiasis, Clotrimazole, Drug Resistance, Microbial, Electrophoresis, Humans, Karyotyping, Male, Mouth, Prospective Studies, Risk Factors, HIV Infections, Fluconazole, Treatment Outcome, AIDS-Related Opportunistic Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review